Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT04429074
Other study ID # RECHMPL20_0348
Secondary ID
Status Completed
Phase
First received
Last updated
Start date December 1, 2019
Est. completion date June 1, 2020

Study information

Verified date June 2020
Source University Hospital, Montpellier
Contact n/a
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

This study aimed to determine whether registrar involvement in minimally invasive distal pancreatectomy (MIDP) was associated with adverse outcomes.


Description:

From January 2009 to March 2020, data of all consecutive patients requiring distal pancreatectomy in our public tertiary hospital were prospectively collected and retrospectively analyzed.

Registrars were progressively involved for MIDP since 2009 and their experience was: < 5 open pancreatic resections, < 5 MIDP and at least 30 advanced minimally invasive gastrointestinal resections.

Outcome of patients who underwent either distal pancreatectomy by the consultant or registrars were compared.

Our primary outcome was the conversion rate. The secondary outcomes were 90-days postoperative outcomes including CR-POPF defined and classified according to the 2016 ISGPF definition.


Recruitment information / eligibility

Status Completed
Enrollment 71
Est. completion date June 1, 2020
Est. primary completion date December 30, 2019
Accepts healthy volunteers No
Gender All
Age group 18 Years to 99 Years
Eligibility Inclusion criteria:

- Patients who underwent minimally invasive distale pancreatectomy for benign or borderline pathology between 2009-2020

Exclusion criteria:

- open distal pancreatectomy

- minimally invasive distal pancreatectomy for pancreatic cancer

- 20 first consecutive patients operated on by the consultant (learning curve)

Study Design


Related Conditions & MeSH terms

  • Minimally Invasive Distal Pancreatectomy

Intervention

Procedure:
Minimally invasive distal pancreatectomy
Minimally invasive distal pancreatectomy

Locations

Country Name City State
France Uhmontpellier Montpellier

Sponsors (1)

Lead Sponsor Collaborator
University Hospital, Montpellier

Country where clinical trial is conducted

France, 

Outcome

Type Measure Description Time frame Safety issue
Primary open conversion rate Necessity to swith from minimally invasive approach to open approach during laparoscopy 1 day
Secondary Duration of surgery Duration of surgery 1 day
Secondary Intraoperative bloodloss Intraoperative bloodloss 1 day
Secondary Intraoperative transfusion Intraoperative transfusion 1 day
Secondary severe complications Clavien Dindo>3 severe complications Clavien Dindo>3 90 days postoperative
Secondary postoperative complications postoperative complications 90 days postoperative
Secondary clinically relevant postoperative fistula clinically relevant postoperative fistula (2016 ISGPF definition) 90 days postoperative
Secondary lenght of hospital stay lenght of hospital stay 90 days postoperative
Secondary readmission rate readmission rate 90 days postoperative
Secondary reoperation rate reoperation rate 90 days postoperative